Abstract Details
Activity Number:
|
377
|
Type:
|
Topic Contributed
|
Date/Time:
|
Tuesday, August 5, 2014 : 2:00 PM to 3:50 PM
|
Sponsor:
|
Biopharmaceutical Section
|
Abstract #313019
|
View Presentation
|
Title:
|
Designing Phase III Trials to Optimize the Value of a Portfolio
|
Author(s):
|
Nitin Patel*+ and Suresh Ankolekar
|
Companies:
|
Cytel and Maastricht School of Management
|
Keywords:
|
Clinical Trials ;
Optimization ;
Portfolio ;
Budget allocation ;
Adaptive design ;
Net Present Value
|
Abstract:
|
We develop a value-driven approach to optimizing pharmaceutical portfolios that integrates inputs from clinical research, clinical operations and commercial functions. Our approach highlights the importance of clinical trial parameters such as sample size and interim looks in adaptive designs. We will describe a Stochastic Integer Programming (SIP) implementation of a Bayesian decision analysis that optimally allocates a drug development budget in a Phase 3 portfolio. The SIP uses Expected Net Present Value (ENPV) as the optimizing criterion and includes out-sourcing, in-sourcing, and partnering opportunities. We show how this model can be used to control risk and investigate the impact of adaptive designs. We show how adaptive designs can attract investment by financial firms by reducing and quantifying risk.
|
Authors who are presenting talks have a * after their name.
Back to the full JSM 2014 program
|
2014 JSM Online Program Home
For information, contact jsm@amstat.org or phone (888) 231-3473.
If you have questions about the Professional Development program, please contact the Education Department.
The views expressed here are those of the individual authors and not necessarily those of the JSM sponsors, their officers, or their staff.
Copyright © American Statistical Association.